Current Report Filing (8-k)
July 11 2018 - 6:05AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR
15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
|
|
July 3,
2018
|
|
|
|
|
|
|
|
|
|
|
NANOVIRICIDES, INC.
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
|
Nevada
|
|
001-36081
|
|
76-0674577
|
(State or Other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
1
Controls Drive,
Shelton, Connecticut
|
|
06484
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(203) 937-6137
(Registrant's Telephone Number, Including
Area Code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 3.01.
|
Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
|
On July 3, 2018, NanoViricides,
Inc. (the “Company”) received a notice from the New York Stock Exchange (the “NYSE”) indicating that
the Company is not in compliance with the NYSE’s continued listing requirements set forth in Part 8 of the NYSE American
Company Guide (the “Company Guide”). The NYSE noted that the Company is not in compliance with Section 803(B)(2)(a)
of the Company Guide in that it no longer has at least three members on the audit committee, effective as of June 29, 2018 when
Dr. Mukund Kulkarni advised the Company that he resigned as a member of its audit committee.
The NYSE informed the
Company that, under the NYSE's rules, the Company will have until the earlier of its next annual meeting or one year from the occurrence
of the event that caused the failure to comply with the audit committee composition requirements, provided, however, that if the
annual shareholders’ meeting occurs no later than 180 days following the event that caused the failure to comply with these
requirements, the Company shall instead have 180 days from such event to regain compliance.
Under the NYSE's rules,
the Company will have until the earlier of its next annual meeting or one year from the occurrence of the event that caused the
failure to comply with the board of directors composition requirements, provided, however, that if the annual shareholders’
meeting occurs no later than 180 days following the event that caused the failure to comply with these requirements, the Company
shall instead have 180 days from such event to regain compliance.
On July 10,
2018, Dr. Kulkarni advised the Company that he rescinded his resignation as a member of the audit committee and the Company accepted
same.
|
Item 5.02.
|
Departure of Directors or Certain Officers.
|
On
July 10, 2018, Dr. Milton Boniuk resigned as a Director of the Company and as a member of its audit, compensation and nominating
committees. The reasons for Dr. Boniuk’s resignation are set forth in the letter attached hereto as Exhibit 17.1 hereto.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE
SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO
DULY AUTHORIZED.
|
NANOVIRICIDES,
INC.
|
|
|
|
|
|
Date: July 10, 2018
|
By:
|
/s/ Meeta Vyas
|
|
|
Name: Meeta Vyas
Title: Chief Financial Officer
|
|
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Aug 2024 to Sep 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Sep 2023 to Sep 2024